Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of hepatocyte proliferation. [GOC:BHF, GOC:mah]
Negative regulation of hepatocyte proliferation is a tightly controlled process that ensures liver homeostasis. It involves a complex interplay of signaling pathways, transcription factors, and growth inhibitors that act to restrict the uncontrolled expansion of hepatocytes, the primary cell type of the liver. Here's a detailed breakdown of this process:
**1. Signaling Pathways:**
* **TGF-β (Transforming Growth Factor-beta) Signaling:** TGF-β is a potent inhibitor of hepatocyte proliferation. It activates SMAD proteins, which then translocate to the nucleus and bind to specific DNA sequences, suppressing the expression of genes required for cell cycle progression.
* **Wnt Signaling:** The Wnt pathway, normally involved in cell proliferation, is often downregulated in the context of negative regulation of hepatocyte proliferation. Inactivation of Wnt signaling prevents the accumulation of β-catenin, a key transcription factor that promotes cell division.
* **Hippo Signaling:** The Hippo pathway, also implicated in controlling cell growth, plays a crucial role in suppressing hepatocyte proliferation. Activation of the Hippo pathway leads to the phosphorylation and inhibition of YAP/TAZ, transcription co-activators that promote cell proliferation.
**2. Transcription Factors:**
* **p53:** A tumor suppressor gene, p53 is activated in response to cellular stress and DNA damage. It can directly inhibit the expression of genes involved in cell cycle progression, thus halting hepatocyte proliferation.
* **Rb (Retinoblastoma Protein):** Rb acts as a gatekeeper of the cell cycle, inhibiting cell cycle progression until certain signals, such as growth factors, are received. In the context of negative regulation of hepatocyte proliferation, Rb helps prevent uncontrolled cell division.
**3. Growth Inhibitors:**
* **Hepatocyte Growth Factor (HGF):** While HGF is a potent mitogen (stimulator of cell division) under normal circumstances, its expression and activity are often suppressed during negative regulation of hepatocyte proliferation, contributing to the inhibition of cell growth.
* **Cyclin-dependent Kinase Inhibitors (CKIs):** CKIs, such as p21 and p27, directly block the activity of cyclin-dependent kinases (CDKs), which are essential for cell cycle progression. The upregulation of CKIs can effectively halt hepatocyte proliferation.
* **Myc:** Myc is a proto-oncogene that promotes cell growth and division. In the context of negative regulation of hepatocyte proliferation, Myc activity is often suppressed, contributing to the overall suppression of cell growth.
**4. Cellular Mechanisms:**
* **Senescence:** Senescent cells are cells that have permanently exited the cell cycle. Senescence can be induced by various cellular stresses, including DNA damage, oxidative stress, and telomere shortening. The accumulation of senescent hepatocytes can contribute to the suppression of liver regeneration.
* **Apoptosis:** Apoptosis, or programmed cell death, is a normal process that eliminates damaged or unwanted cells. It plays a role in negative regulation of hepatocyte proliferation by eliminating cells that have lost their ability to properly control their growth.
**5. Liver Microenvironment:**
* **Extracellular Matrix:** Changes in the extracellular matrix (ECM) composition and stiffness can influence hepatocyte proliferation. A rigid and dense ECM can inhibit cell growth, while a more flexible and permissive ECM can promote proliferation.
* **Immune Cells:** Immune cells, particularly macrophages, can contribute to the regulation of hepatocyte proliferation by releasing cytokines and growth factors. For example, macrophages can secrete anti-inflammatory cytokines, which can suppress liver regeneration and contribute to the overall negative regulation of hepatocyte proliferation.
**The Importance of Negative Regulation of Hepatocyte Proliferation:**
The careful control of hepatocyte proliferation is critical for maintaining liver homeostasis. Uncontrolled hepatocyte proliferation can lead to liver damage and disease, including cirrhosis and cancer. The negative regulation of hepatocyte proliferation is a complex and multifaceted process that ensures that liver cells only divide when it is necessary and safe to do so.'
"
Protein | Definition | Taxonomy |
---|---|---|
Carboxypeptidase B2 | A carboxypeptidase B2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q96IY4] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
benzylsuccinic acid | 2-benzylsuccinic acid : A dicarboxylic acid consisting of succinic acid carrying a 2-benzyl substituent. benzylsuccinic acid: inhibitor of carboxypeptidase A | dicarboxylic acid | bacterial xenobiotic metabolite |
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2. | aromatic ether; C-nitro compound; sulfonamide | antineoplastic agent; cyclooxygenase 2 inhibitor |
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
sq 24798 | 2-mercaptomethyl-5-guanidinopentanoic acid: structure | ||
anabaenopeptin b | anabaenopeptin B: from cyanobacteria Planktothrix (Oscillatoria) rubescens |